Objective: This pilot study investigated whether a home exercise video programme could improve exercise tolerance and breathlessness in patients with moderate to severe chronic obstructive pulmonary disease.
Methods: Twenty subjects completed the study after being randomized to intervention or control. The intervention group (n=10), watched a 19-min video on the benefits of exercise for patients with chronic obstructive pulmonary disease and were given a 30-min exercise video, an illustrated exercise diary and an educational booklet about chronic obstructive pulmonary disease, for use at home. They were advised to follow the exercise video programme 4 times a week for 6 weeks. The control group (n=10) received the chronic obstructive pulmonary disease educational booklet only. Exercise tolerance was measured using the Incremental Shuttle Walk Test and breathlessness by the self-reported Chronic Respiratory Questionnaire.
Results: The median change in the Incremental Shuttle Walk Test and breathlessness score significantly improved in the intervention group compared with the control (+45 m vs -15 m, p=0.013 and +0.5 vs -0.1 Chronic Respiratory Questionnaire units, p=0.042). The other findings for the self-reported Chronic Respiratory Questionnaire showed significant improvements in the intervention group for emotion (p<0.001) and fatigue (p=0.012), but not mastery (p=0.253).
Conclusion: This pilot study suggests that participation in a home exercise video programme may benefit people with chronic obstructive pulmonary disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2340/16501977-0308 | DOI Listing |
Respir Res
January 2025
Microbial Antibodies and Technologies, Research and Early Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by airway obstruction and inflammation. Non-typeable Haemophilus influenzae (NTHi) lung infections are common in COPD, promoting frequent exacerbations and accelerated lung function decline. The relationship with immune responses and NTHi are poorly understood.
View Article and Find Full Text PDFEur J Intern Med
January 2025
Internal Medicine and Stroke Care ward, Department of Promoting Health, Maternal-Infant. Excellence and Internal and Specialized Medicine (Promise) G. D'Alessandro, University of Palermo, Palermo Italy.
Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are known to increase the risk of cardiovascular (CV) events and mortality. However, the temporal trend of this risk has not fully elucidated. This systematic review and meta-analysis aims to quantify the risk of CV events after COPD exacerbations over different time periods.
View Article and Find Full Text PDFDrug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFBMJ Open Respir Res
January 2025
Department of Medicine, The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, USA
Background: An estimated 10-30% of people with COVID-19 experience debilitating long-term symptoms or long covid. Underlying health conditions associated with chronic inflammation may increase the risk of long covid.
Methods: We conducted a systematic review and meta-analysis to examine whether long covid risk was altered by pre-existing asthma or chronic obstructive pulmonary disease (COPD) in adults.
Preliminary test a two stage, self-determination theory (SDT) and participation-based physical activity and peer support intervention for individuals with Chronic Obstructive Pulmonary Disease (COPD). In Stage 1, four focus groups were conducted to provide insights about individuals' needs and experiences with physical activity. In Stage 2, four individuals with COPD aged 76-90 years (50% female) participated in an eight-week online physical activity and peer support intervention.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!